ArticleNature2020
LifeTime and improving European healthcare through cell-based interceptive medicine.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 82 papers.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
12.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 169 citations in OpenAlex.
- OpenDVP: an experimental and computational framework for community-empowered deep visual proteomics.Nature methods · 2026Article
- RAGCell: retrieval-augmented generation as supervision for versatile single-cell analysis.Bioinformatics (Oxford, England) · 2026Article
- Multi-platform integration of brain and CSF proteomes reveals biomarker panels for Alzheimer's disease.Briefings in bioinformatics · 2026Article
- ScRDAVis: An R shiny application for single-cell transcriptome data analysis and visualization.PLoS computational biology · 2025Article
- Characterization of human CMV-specific CD8Cell reports methods · 2025Article
- Cell Marker Accordion: interpretable single-cell and spatial omics annotation in health and disease.Nature communications · 2025Article
- Cell Marker Accordion: interpretable single-cell and spatial omics annotation in health and disease.bioRxiv : the preprint server for biology · 2025Article
- Single-Cell Sequencing: Genomic and Transcriptomic Approaches in Cancer Cell Biology.International journal of molecular sciences · 2025Review
- Multiplexing cortical brain organoids for the longitudinal dissection of developmental traits at single-cell resolution.Nature methods · 2025Article
- Liquid biopsy in cancer management: Integrating diagnostics and clinical applications.Practical laboratory medicine · 2025Review
- How to build the virtual cell with artificial intelligence: Priorities and opportunities.Cell · 2024Article
- π-HuB: the proteomic navigator of the human body.Nature · 2024Review
- A mini-review on perturbation modelling across single-cell omic modalities.Computational and structural biotechnology journal · 2024Review
- How to Build the Virtual Cell with Artificial Intelligence: Priorities and Opportunities.ArXiv · 2024Article
- StaVia: spatially and temporally aware cartography with higher-order random walks for cell atlases.Genome biology · 2024Article
- Towards a Treatment for Leukodystrophy Using Cell-Based Interception and Precision Medicine.Biomolecules · 2024Review
- Panpipes: a pipeline for multiomic single-cell and spatial transcriptomic data analysis.Genome biology · 2024Article
- Mitochondrial genetics through the lens of single-cell multi-omics.Nature genetics · 2024Review
- A new atlas to study embryonic cell types in Xenopus.Developmental biology · 2024Article
- DOT: a flexible multi-objective optimization framework for transferring features across single-cell and spatial omics.Nature communications · 2024Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
51 authors at 20 institutions in 19 countries.
Nikolaus Rajewsky *Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. rajewsky@mdc-berlin.de.ORCID 0000-0002-4785-4332
Geneviève Almouzni *Institut Curie, CNRS, PSL Research University, Sorbonne Université, Nuclear Dynamics Unit, Equipe Labellisée Ligue contre le cancer, Paris, France. genevieve.almouzni@curie.fr.ORCID 0000-0001-5570-0723
Stanislaw A Gorski *Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany. stan.gorski@mdc-berlin.de.ORCID 0000-0003-0539-3395
Stein AertsVIB Center for Brain and Disease Research, Leuven, Belgium.ORCID 0000-0002-8006-0315
Ido AmitDepartment of Immunology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0003-2968-877X
Michela G BerteroCentre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Barcelona, Spain.
Christoph BockCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0001-6091-3088
Annelien L BredenoordDepartment of Medical Humanities, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-7542-8963
Giacomo CavalliInstitute of Human Genetics, UMR 9002, CNRS and University of Montpellier, Montpellier, France.ORCID 0000-0003-3709-3469
Susanna ChioccaDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0002-9721-0850
Hans CleversHubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht, The Netherlands.ORCID 0000-0002-3077-5582
Bart De StrooperVIB Center for Brain and Disease Research, Leuven, Belgium.
Angelika EggertBerlin Institute of Health (BIH), Berlin, Germany.
Jan EllenbergCell Biology and Biophysics Unit, European Molecular Biology Laboratory, Heidelberg, Germany.ORCID 0000-0001-5909-701X
Xosé M FernándezInstitut Curie, PSL Research University, Paris, France.ORCID 0000-0001-7139-6215
Marek FiglerowiczInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Susan M GasserFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.ORCID 0000-0003-3610-9123
Norbert HubnerCharité-Universitätsmedizin, Berlin, Germany.ORCID 0000-0002-1218-6223
Jørgen KjemsDepartment of Molecular Biology and Genetics (MBG), Aarhus University, Aarhus, Denmark.
Jürgen A KnoblichInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.ORCID 0000-0002-6751-3404
Grietje KrabbeBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Peter LichterDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-2960-5279
Sten LinnarssonDivision of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-3491-3444
Jean-Christophe MarineLaboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, KU Leuven, Leuven, Belgium.
John C MarioniEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.ORCID 0000-0001-9092-0852
Marc A Marti-RenomCentre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0002-0151-4279
Mihai G NeteaDepartment of Internal Medicine, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0003-2421-6052
Dörthe NickelInstitut Curie, PSL Research University, Paris, France.
Marcelo NollmannCentre de Biochimie Structurale, CNRS UMR 5048, INSERM U1054, Université de Montpellier, Montpellier, France.ORCID 0000-0003-3339-2349
Halina R NovakVIB Technology Watch, Ghent, Belgium.
Helen ParkinsonEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.
Stefano PiccoloDepartment of Molecular Medicine, University of Padua School of Medicine, Padua, Italy.ORCID 0000-0002-1600-3092
Inês PinheiroInstitut Curie, CNRS, PSL Research University, Sorbonne Université, Nuclear Dynamics Unit, Equipe Labellisée Ligue contre le cancer, Paris, France.
Ana PomboBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.ORCID 0000-0002-7493-6288
Christian PoppBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Wolf ReikWellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.ORCID 0000-0003-0216-9881
Sergio Roman-RomanDepartment of Translational Research, Institut Curie, PSL Research University, Paris, France.
Philip RosenstielInstitute of Clinical Molecular Biology, Kiel University, Kiel, Germany.
Joachim L SchultzeLife and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.ORCID 0000-0003-2812-9853
Oliver StegleEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.
Amos TanayDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0001-9419-3824
Giuseppe TestaDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Dimitris ThanosBiomedical Research Foundation, Academy of Athens, Athens, Greece.
Fabian J TheisInstitute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.ORCID 0000-0002-2419-1943
Maria-Elena Torres-PadillaInstitute of Epigenetics and Stem Cells (IES), Helmholtz Zentrum München - German Research Center for Environmental Health, Munich, Germany.ORCID 0000-0002-1020-2074
Alfonso ValenciaICREA, Barcelona, Spain.
Céline VallotDepartment of Translational Research, Institut Curie, PSL Research University, Paris, France.ORCID 0000-0003-1601-2359
Alexander van OudenaardenHubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht, The Netherlands.ORCID 0000-0002-9442-3551
Marie VidalBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.ORCID 0000-0003-1186-9994
Thierry VoetDepartment of Human Genetics, KU Leuven, Leuven, Belgium.
LifeTime Community Working Groups
Max Delbrück Center · DECentre National de la Recherche Scientifique · FRUniversity of Antwerp · BEUniversity of Milan · ITEuropean Bioinformatics Institute · GBUniversité Paris Sciences et Lettres · FRUniversity of Bonn · DEEuropean Molecular Biology Laboratory · DEGerman Center for Neurodegenerative Diseases · DEHelmholtz Zentrum München · DERoyal Netherlands Academy of Arts and Sciences · NLUK Dementia Research Institute · GBUniversity of Eastern Finland · FIUniversity of Rome Tor Vergata · ITWeizmann Institute of Science · ILBabraham Institute · GBErasmus MC · NLRadboud University Nijmegen · NLUniversitat Pompeu Fabra · ESUniversity Medical Center Utrecht · NL
Funding
Cancer Research UK 22231
Abstract
Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.
Indexed as
Cell- and Tissue-Based TherapyPathologySingle-Cell AnalysisArtificial IntelligenceDelivery of Health CareEarly DiagnosisEducation, MedicalEuropeFemaleHealthHumansLegislation, MedicalMaleMedicine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.